Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 3
2016 1
2017 2
2018 5
2019 9
2020 5
2021 8
2022 8
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Paradigm Shift in Gastric Cancer Prevention: Harnessing the Potential of Aristolochia olivieri Extract.
Micucci M, Stella Bartoletti A, Abdullah FO, Burattini S, Versari I, Canale M, D'Agostino F, Roncarati D, Piatti D, Sagratini G, Caprioli G, Mari M, Retini M, Faenza I, Battistelli M, Salucci S. Micucci M, et al. Among authors: canale m. Int J Mol Sci. 2023 Nov 6;24(21):16003. doi: 10.3390/ijms242116003. Int J Mol Sci. 2023. PMID: 37958986 Free PMC article.
Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
Urbini M, Marisi G, Azzali I, Bartolini G, Chiadini E, Capelli L, Tedaldi G, Angeli D, Canale M, Molinari C, Rebuzzi F, Virga A, Prochowski Iamurri A, Matteucci L, Sullo FG, Debonis SA, Gallio C, Frassineti GL, Martinelli G, Ulivi P, Passardi A. Urbini M, et al. Among authors: canale m. JCO Precis Oncol. 2023 Sep;7:e2200694. doi: 10.1200/PO.22.00694. JCO Precis Oncol. 2023. PMID: 37656949
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G, Azzali I, Passardi A, Rebuzzi F, Bartolini G, Urbini M, Canale M, Molinari C, Matteucci L, Sullo FG, Debonis SA, Gallio C, Gallo G, Frassineti GL, Ulivi P. Marisi G, et al. Among authors: canale m. Sci Rep. 2023 Aug 9;13(1):12921. doi: 10.1038/s41598-023-40220-7. Sci Rep. 2023. PMID: 37558720 Free PMC article. Clinical Trial.
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.
Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. Niger M, et al. Among authors: canale m. Mol Oncol. 2022 Jul;16(14):2733-2746. doi: 10.1002/1878-0261.13256. Epub 2022 Jun 13. Mol Oncol. 2022. PMID: 35621918 Free PMC article.
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.
Bronte G, Petracci E, De Matteis S, Canale M, Zampiva I, Priano I, Cravero P, Andrikou K, Burgio MA, Ulivi P, Delmonte A, Crinò L. Bronte G, et al. Among authors: canale m. Front Immunol. 2022 Apr 13;13:866561. doi: 10.3389/fimmu.2022.866561. eCollection 2022. Front Immunol. 2022. PMID: 35493483 Free PMC article.
44 results